首页> 外文期刊>Phytotherapy research: PTR >Effect of an aqueous extract ofTerminalia chebulaon endothelial dysfunction, systemic inflammation, and lipid profile in type 2 diabetes mellitus: A randomized double-blind, placebo-controlled clinical study
【24h】

Effect of an aqueous extract ofTerminalia chebulaon endothelial dysfunction, systemic inflammation, and lipid profile in type 2 diabetes mellitus: A randomized double-blind, placebo-controlled clinical study

机译:2型糖尿病患者患有母细胞含量的内皮功能障碍,全身炎症和脂质谱的影响:随机双盲,安慰剂对照临床研究

获取原文
获取原文并翻译 | 示例
       

摘要

Endothelial dysfunction is a crucial complication in type 2 diabetic patients, related to cardiovascular risk.Terminalia chebula(TC), a traditional ayurvedic herb, is known for its antioxidant and antihyperlipidemic activity. A prospective, randomized, double-blind, placebo-controlled clinical study was undertaken to evaluate the effects of an aqueous extract ofT. chebula250 and 500 mg versus placebo on endothelial dysfunction and biomarkers of oxidative stress in type 2 diabetic patients. A total of 60 eligible patients were randomized to receive eitherT. chebula250 mg,T. chebula500 mg, or placebo twice daily for 12 weeks. The subjects were assessed based on the endothelial function, the levels of nitric oxide, malondialdehyde, glutathione, high sensitivity C-reactive protein, glycosylated hemoglobin, and lipid profile at baseline and after 12 weeks of treatment. Treatment withT. chebula250 mg andT. chebula500 mg for 12 weeks significantly improved the endothelial function (reflection index) compared to placebo (absolute changes: -T. chebula250: -2.55 +/- 1.82% vs.T. chebula500: -5.21 +/- 2.41% vs. placebo: 1.40 +/- 2.11%). Other cardiovascular risk indicators were also significantly ameliorated in the treatment groups compared to placebo. In conclusion,T. chebula(especially, 500 mg BID dose) significantly minimized the cardiovascular risk factors in patients with type 2 diabetes compared to placebo.
机译:内皮功能障碍是2型糖尿病患者的重要并发症,与心血管风险有关。诃子(Terminalia chebula,TC)是一种传统的阿育吠陀草药,以其抗氧化和降血脂活性而闻名。进行了一项前瞻性、随机、双盲、安慰剂对照临床研究,以评估水提取物ofT的效果。chebula250和500mg与安慰剂对2型糖尿病患者内皮功能障碍和氧化应激生物标志物的影响。共有60名符合条件的患者随机接受eitherT治疗。chebula250 mg、T.chebula500 mg或安慰剂,每天两次,持续12周。在基线检查和治疗12周后,根据内皮功能、一氧化氮、丙二醛、谷胱甘肽、高敏C反应蛋白、糖基化血红蛋白和血脂水平对受试者进行评估。用T治疗。chebula250毫克安替比林。与安慰剂相比,持续12周的chebula500 mg显著改善内皮功能(反射指数)(绝对变化:-T.chebula250:-2.55+/-1.82%与T.chebula500:-5.21+/-2.41%与安慰剂:1.40+/-2.11%)。与安慰剂相比,治疗组的其他心血管风险指标也显著改善。总之,与安慰剂相比,切布拉锥虫(尤其是500 mg BID剂量)显著降低了2型糖尿病患者的心血管风险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号